In contrast, the TNBC subgroup showed a markedly heightened expression of IL-6 and MCP-1, both at the gene and protein levels, reinforcing their potential as biomarkers for aggressive breast cancer phenotypes. This evidence concerns the gene CCL2 and breast cancer.